Table 4. Reclassification of patients in the validation series (n=354) on the basis of 10-year predicted sarcoma-specific survival.
|
SAM model
|
||||
|---|---|---|---|---|
| ⩾80% | 40–80% | <40% | Total | |
| Cases, by predicted survival a | ||||
| ⩾80% | 10 | 6 | 16 | |
| 40–80% | 2 | 55 | 11 | 68 |
| <40% | 9 | 18 | 27 | |
| Total | 12 | 70 | 29 | 111 |
| Non-cases, by predicted survival a | ||||
| ⩾80% | 105 | 10 | 115 | |
| 40–80% | 31 | 75 | 6 | 112 |
| <40% | 2 | 14 | 16 | |
| Total | 136 | 87 | 20 | 243 |
Abbreviation: SAM=the proposed extended model.
a
10-year predicted sarcoma-specific survival on the basis of SIN (size, invasion, necrosis) model prognostic factors only.